Peramivir
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), BioCryst Pharmaceuticals, Johns Hopkins University, Chinese University of Hong Kong, University of Oxford
Conditions
Acute, Uncomplicated Human InfluenzaCoughFatigueHeadacheInfluenzaInfluenza, HumanMyalgiaNasal Congestion
Phase 1
Phase 2
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
CompletedNCT00705406
Start: 2008-07-31End: 2009-10-31Updated: 2015-02-16
Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections
CompletedNCT02665351
Start: 2011-02-28End: 2014-03-31Updated: 2016-01-29
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
RecruitingNCT05648448
Start: 2023-02-22End: 2027-01-01Target: 3000Updated: 2026-02-19
Phase 3
Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
TerminatedNCT00610935
Start: 2008-01-31End: 2008-02-29Updated: 2021-03-17
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
CompletedNCT00957996
Start: 2009-10-31End: 2011-08-31Updated: 2015-02-12
A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
TerminatedNCT01224795
Start: 2010-10-31End: 2010-11-30Updated: 2015-01-06
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
CompletedNCT02369159
Start: 2015-03-11End: 2020-05-14Updated: 2021-03-23
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
CompletedNCT02635724
Start: 2015-12-31End: 2018-09-30Updated: 2021-03-23